Johns Hopkins ABX Guide
Obiltoxaximab
INDICATIONS
FDA
FDA
- Treatment of inhalational anthrax due to Bacillus anthracis (in combination with appropriate antibacterial drugs)
- Prevention of inhalational anthrax when alternative agents are unavailable
- CDC guidance: Choose a single antitoxin if no antimicrobial drugs are available.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 10, 2026
Citation
Auwaerter, Paul G, and Kathryn Dzintars. "Obiltoxaximab." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/0.0/Obiltoxaximab.
Auwaerter PG, Dzintars K. Obiltoxaximab. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/0.0/Obiltoxaximab. Accessed March 22, 2026.
Auwaerter, P. G., & Dzintars, K. (2026). Obiltoxaximab. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/0.0/Obiltoxaximab
Auwaerter PG, Dzintars K. Obiltoxaximab [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 March 22]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/0.0/Obiltoxaximab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Obiltoxaximab
ID - 540668
A1 - Auwaerter,Paul,M.D.
AU - Dzintars,Kathryn,PharmD, BCPS
Y1 - 2026/03/10/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/0.0/Obiltoxaximab
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
